72605-86-8Relevant articles and documents
Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor
Shen, Hong C.,Ding, Fa-Xiang,Luell, Silvi,Forrest, Michael J.,Carballo-Jane, Ester,Wu, Kenneth K.,Wu, Tsuei-Ju,Cheng, Kang,Wilsie, Larissa C.,Krsmanovic, Mihajlo L.,Taggart, Andrew K.,Ren, Ning,Cai, Tian-Quan,Deng, Qiaolin,Chen, Qing,Wang, Junying,Wolff, Michael S.,Tong, Xinchun,Holt, Tom G.,Waters, M. Gerard,Hammond, Milton L.,Tata, James R.,Colletti, Steven L.
, p. 6303 - 6306 (2008/04/12)
Biaryl anthranilides are reported as potent and selective full agonists for the high affinity niacin receptor GPR109A. The SAR presented outlines approaches to reduce serum shift and both CYPCYP2C8 and CYP2C9 liabilities, while improving PK and maintainin
Tyrosine kinase inhibitors
-
Page/Page column 25, (2010/02/14)
The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such
7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
-
, (2008/06/13)
7-Methoxy-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid, useful as an antiallergic agent, and prepared by reaction of 5-methoxyanthranilic acid with methyl 2-chlorothiazole-5-carboxylate, and subsequent hydrolysis, is described.